Previous 10 | Next 10 |
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Johnson & Johnson (NYSE: JNJ ) stock is up for 2022 in a down market Credit goes to its medical devices and anti-cancer drug Darzalex JNJ’s dividend has been rising for six decades, making it a safe st...
Multiple epcoritamab (DuoBody ® -CD3xCD20) studies will be presented showcasing preliminary efficacy and safety findings in a variety of patient populations in need of treatment options Several abstracts evaluating Genmab owned and partnered programs accepted for pr...
The following slide deck was published by Genmab A/S in conjunction with their 2022 Q1 earnings call. For further details see: Genmab A/S 2022 Q1 - Results - Earnings Call Presentation
Image source: The Motley Fool. Genmab A/S (NASDAQ: GMAB) Q1 2022 Earnings Call May 11, 2022 , 12:00 p.m. ET Operator Continue reading For further details see: Genmab A/S (GMAB) Q1 2022 Earnings Call Transcript
Genmab A/S (GMAB) Q1 2022 Earning Conference Call May 11, 2022 12:00 PM ET Company Participants Jan van de Winkel - President and Chief Executive Officer Anthony Pagano - Chief Financial Officer Conference Call Participants Peter Virgil - Citigroup James Gordon - JPMorgan Wimal Kapadia - Bern...
Genmab A/S press release (GMAB): Q1 Operating Profit of DKK 514M. Revenue of DKK 2.12B. FY22 revenue guidance in the range of DKK 11B-12B. Operating profit guidance in the range of DKK 3.2B-4.8B. For further details see: Genmab Q1 Operating Profit of DKK 514M, Revenue of DKK 2.12B
Genmab A/S (GMAB) is scheduled to announce Q1 earnings results on Wednesday, May 11th, before market open. The consensus EPS Estimate is $0.19 (-98.9% Y/Y) and the consensus Revenue Estimate is $294.12M (-81.4% Y/Y). Over the last 3 months, EPS estimates have seen 0 upward revisions ...
The overall price growth since the inception of IDNA is quite impressive, considering the huge impact of the Covid-19 pandemic in the U.S. equity market. Huge price loss in the past 12 months, but positive price gain in the past three years, is an apparently visible trend in Genomics-...
AbbVie and Genmab Announce Topline Results for Epcoritamab (DuoBody®-CD3xCD20) from Phase 1/2 Trial in Patients with Relapsed/Refractory Large B-cell Lymphoma (LBCL) PR Newswire - Based on topline results from the EPCORE™ NHL-1 clinical trial, AbbVie and Ge...
Company Announcement Based on the topline results from the EPCORE™ NHL-1 clinical trial, Genmab and AbbVie will engage global regulatory authorities to discuss next steps Data from the clinical trial to be presented at a future medical meeting Large B-...
News, Short Squeeze, Breakout and More Instantly...
2024-08-01 01:18:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
A look at the top 10 most actives in the United States Innovative Eyewear Inc. (LUCY) rose 78.0% to $0.58749 on volume of 130,454,575 shares Ocean Power Technologies Inc. (OPTT) rose 29.6% to $0.2073 on volume of 51,927,154 shares Cosmos Health Inc. (COSM) rose 64.9% to $1.12 on volume of...
Company Announcement Positive CHMP opinion based on results from the Phase 1/2 EPCORE ® NHL-1 study FL is the second most common type of NHL and accounts for approximately 20-30 percent of all global cases If approved, epcoritamab (TEPKINLY ® ...